Core Viewpoint - A shareholder class action lawsuit has been filed against Altimmune, Inc. alleging that the company made materially false and misleading statements regarding the results of the IMPACT Phase 2b MASH trial, particularly concerning inflated expectations and undisclosed adverse information related to the placebo group's responses [1] Group 1: Lawsuit Details - The lawsuit claims that Altimmune consistently promoted inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial [1] - It is alleged that the company concealed higher responses in the placebo group, which could negatively impact the topline results [1] Group 2: Shareholder Information - Shareholders who purchased Altimmune shares between August 10, 2023, and June 25, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is October 6, 2025 [3] Group 3: Legal Representation - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3] - The firm has been recognized as an ISS top-rated securities litigation law firm for 2021, 2022, and 2023 [3]

Financial Transactions - ALT5 Sigma 完成了由 World Liberty Financial 牵头的 15 亿美元的注册直接发行和私募 [1] Strategic Partnerships & Leadership Changes - ALT5 Sigma 将采纳 WLFI Treasury Strategy，持有约 WLFI 总供应量的 7.5% [1] - WLFI 的 CEO Zach Witkoff 被任命为 ALT5 的董事长 [1] - Eric Trump 加入 ALT5 担任董事 [1] - Kraken 将担任 ALT5 的资产管理公司 [1]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which did not meet key statistical significance markers [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - The lawsuit claims that Altimmune created a false impression of reliable information regarding trial results, while concealing negative data that would impact the topline results [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for investors [4]. - Investors wishing to serve as lead plaintiff must file their motion by October 6, 2025 [1][3]. Group 3: Trial Results - Altimmune's IMPACT Phase 2b MASH trial failed to achieve statistical significance for the primary endpoint related to fibrosis reduction, contrary to the company's previous claims [5]. - The lawsuit alleges that the company concealed higher responses in the placebo group, which negatively affected the trial's topline results [5].

Group 1 - A class action lawsuit has been filed against Altimmune Inc. on behalf of investors who acquired its securities between August 10, 2023, and June 25, 2025 [1][2] - The lawsuit follows the announcement of disappointing results from the IMPACT Phase 2b trial of Pemvidutide for treating MASH, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3] - Following the trial results announcement, Altimmune's stock price plummeted by 53.2%, closing at $3.61 on June 26, 2025, down from $7.71 the previous day [4] Group 2 - Altimmune is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH [2] - The company had previously made positive statements regarding the trial results, which ultimately did not materialize as expected [3]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Faruq ...

Altimmune (ALT) Q2 2025 Earnings Call August 12, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Altimmune Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. A reminder, this call is being recorded. I'll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan, Investor Relations Adviser t ...

Exhibit 99.1 New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET Altimmune Announces Second Quarter 2025 Financial Results and Business Update Positive data from the IMPACT Phase 2b trial reinforces the p ...

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Altimmune securities between August 10, 2023, and June 25, 2025, with a deadline of October 6, 2025, for investors to apply as lead plaintiffs [1]. - The complaint highlights that Altimmune's announcement on June 26, 2025, revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction in the trial, despite prior inflated expectations [3]. Group 2: Stock Price Impact - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [4].

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submi ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effectiv ...